---
layout: full_article
title: "The ACUTE SIDE EFFECTS AND QUALITY OF LIFE IN HEAD AND NECK CANCER PATIENTS WHO UNDERWENT RADIOTHERAPY IN BALI, INDONESIA"
author: "Vania Sukarno, Ngakan Putu Daksa Ganapati, Fanny Deantri"
categories: eum
comments: true
---

<div><img src="https://jurnal.harianregional.com/media/105396-1.jpg" alt="" style="width:129pt;height:77pt;">
</div><br clear="all">
<p><span class="font4">ISSN: 2597-8012 JURNAL MEDIKA UDAYANA, VOL. 13 NO.02, FEBRUARI, 2024</span></p>
<div><img src="https://jurnal.harianregional.com/media/105396-2.jpg" alt="" style="width:90pt;height:15pt;">
</div><br clear="all"><img src="https://jurnal.harianregional.com/media/105396-3.jpg" alt="" style="width:78pt;height:20pt;">
<p><span class="font4">Received: 2023-08-05 Revision: 2023-11-28 Accepted: 02-01-2024</span></p>
<p><span class="font6" style="font-weight:bold;">ACUTE SIDE EFFECTS AND QUALITY OF LIFE IN HEAD AND NECK CANCER PATIENTS WHO UNDERWENT RADIOTHERAPY IN BALI, INDONESIA</span></p>
<p><span class="font5" style="font-weight:bold;">Ngakan Putu Daksa Ganapati <sup>1</sup>, Vania Sukarno <sup>2</sup>, Fanny Deantri <sup>2 </sup></span><span class="font5"><sup>1</sup> Department of Radiology , Prof. Dr. IGNG Ngoerah Hospital, Bali <sup>2</sup>Faculty of Medicine , Udayana University , Bali e-mail: </span><a href="mailto:putudaksa@gmail.com"><span class="font5">putudaksa@gmail.com</span></a></p>
<p><span class="font4" style="font-weight:bold;">ABSTRACT</span></p>
<p><span class="font5" style="font-weight:bold;">Background: </span><span class="font5">Radiotherapy is a therapeutic modality for head and neck cancer which kills cancer cells with radiation waves. In addition to damaging cancer cells, radiotherapy also damages healthy body cells around the target tissue. Damage to healthy body cells causes a side effect of toxicity from radiotherapy. Side effects of radiotherapy cause a decrease in quality of life in patients undergoing radiotherapy. As technology advances, there are many types of teletherapy tools being developed.</span></p>
<p><span class="font5" style="font-weight:bold;">Purpose: </span><span class="font5">The aim of this study is to compare the acute side effects and quality of life of the patients who underwent radiotherapy with different equipment; Cobalt-60 and LINAC (Linear Accelerator).</span></p>
<p><span class="font5" style="font-weight:bold;">Patients and Methods: </span><span class="font5">This was an analytic observational study, performed on head and neck cancer patients who underwent radiotherapy between January 2020 and July 2022 at radiotherapy department, RSUP Prof. Dr. IGNG Ngoerah, Bali. We measure patient's quality of life with EORTC QLQ-C30 questionnaire and acute side effects with RTOG grading. The average value and comparison of both teletherapy devices were assessed using cross tabulation and analyzed with Statistical Package for Social Science (SPSS) version 26.0.</span></p>
<p><span class="font5" style="font-weight:bold;">Result: </span><span class="font5">This study admitted 52 patients (35 LINAC and 17 Cobalt-60) who met inclusion and exclusion criteria. Most of the participants in this study were 49-60 years old (50%), male (63.7%), the main location of cancer was in the nasopharynx (84.6%), and the prognosis stage was 4A (57.7%). Comparison between both groups showed p value &gt;0.05 on acute side effects and quality of life. Most patients experienced Grade 1 RTOG side effects on skin, salivary glands, pharynx and esophagus, and larynx. The LINAC group had a higher percentage (94.3%) of “good” general condition compared to the Cobalt 60 group (76.5%). The lowest function scale based on EORTC QLQ-C30 was role function (51.9 ± 31.8), and the highest score of symptoms scale was fatigue (50.0 ± 31.2).</span></p>
<p><span class="font5" style="font-weight:bold;">Conclusion: </span><span class="font5">There are no significant differences in acute side effects and quality of life of patients who underwent radiotherapy with LINAC and Cobalt-60 teletherapy. However, the LINAC group has a larger percentage of “good” general condition compared to Cobalt-60 group.</span></p>
<p><span class="font5" style="font-weight:bold;">Keywords: </span><span class="font5">Cobalt-60., LINAC., Acute Side Effect., Quality of Life., Radiotherapy.</span></p>
<p><span class="font4" style="font-weight:bold;">INTRODUCTION</span></p>
<p><span class="font4">Head and neck cancer can originate from nasopharynx, thyroid, lips and oral cavity, larynx, salivary glands, oropharynx, esophagus and hypopharynx. Head and neck cancer contributed 42,814 new cancer cases or 12.27% of all new cancer cases in Indonesia recorded in The Global Cancer Observatory in 2018. The 6th cause of death in Indonesia. <sup>1</sup> Head and neck cancer is more common in men than women and people aged between 50 and early 60 years in Asian countries. <sup>2</sup></span></p>
<p><span class="font4">Radiotherapy or radiation therapy is a cancer treatment that uses high levels of radiation to kill cancer cells and reduce the size of tumors. On the other hand, radiotherapy not only kills cancer cells, but also healthy cells around them. <sup>3</sup> Radiotherapy with Cobalt 60 uses gamma rays to treat cancer. Starting in the 1950s, cobalt 60 was used as an external therapy to kill cancer cells. Cobalt 60 produces a stable dichromatic emission of 1.25 mega</span></p>
<p><span class="font4">volts and has a half-life of 5.3 years so the radiation source must be replaced periodically. However Cobalt 60 is starting to be replaced by Linear Accelerator (LINAC).<sup>4</sup> Linear Accelerator is a type of machine that accelerates subatomic particles or ions by exposing them to electrical potential in parallel with a straight beam. Various types of particles that can be accelerated according to the engine are protons, electrons and ions. <sup>5</sup></span></p>
<p><span class="font4">LINAC offers precise and versatile treatment with cost advantages but requires a higher initial investment and frequent maintenance. Cobalt, on the other hand, has a longer-lasting radiation source but is less versatile. The choice depends on budget and facility resources.<sup>6</sup></span></p>
<p><span class="font4">Therapy with radiation is strong enough to injure surrounding normal tissue, leaving behind cell damage that triggers a response from the immune system, as well as activating</span></p>
<p><span class="font4">a series of chemical and mechanical events within the cells, causing side effects</span><span class="font2">. </span><span class="font4"><sup>7</sup></span></p>
<p><span class="font4">Side effects of radiotherapy can cause acute and chronic effects. In the late 1970s, further research began to be conducted to share perceptions of the toxicity assessment of radiotherapy use by the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC ). <sup>8</sup>In head and neck cancer radiotherapy, acute side effects focus on toxicity in skin tissue, salivary glands, pharynx, esophagus, and larynx.<sup>9</sup>While the chronic side effects include salivary loss, osteoradionecrosis, dental issues, skin changes, and chronic sinusitis.<sup>10</sup>In this study, the authors compared the side effects of radiation that occurred in head and neck cancer patients who received radiation on a Cobalt-60 machine with patients who received radiation on a Linear Accelerator (LINAC) machine.</span></p><a name="caption1"></a>
<h1><a name="bookmark0"></a><span class="font4" style="font-weight:bold;"><a name="bookmark1"></a>MATERIALS AND METHODS</span></h1>
<p><span class="font4">This is an observational case-control study between January 2020 and July 2022, involving 52 patients diagnosed with head and neck cancer who underwent radiotherapy with Cobalt 60 and LINAC machines with a total dose of 63-70 Gy (divided into 3335 fractions). Data were obtained from RSUP Prof. Dr. IGNG Ngoerah medical record. Inclusion criteria encompassed diagnosis through radiological and anatomical pathology, while exclusion criteria involved non-completion of prescribed therapy and uncooperativeness. The study used total sampling due to a population size of less than 100. Primary data was gathered through patient questionnaires, while secondary data came from specialists' assessments. The analysis, conducted with SPSS Version 26.0.</span></p>
<p><span class="font4">This research was approved by the Ethics Commission of the Faculty of Medicine, Udayana University, Bali (No.1733/UN14.2.2.VII.14/LT/2022). Thirty-five and seventeen patients were divided into LINAC group and Cobalt-60 group, respectively. Unequal sample numbers between groups were due to total sampling method used. All patients were provided with complete information regarding the study and </span><span class="font4" style="font-style:italic;">informed consent </span><span class="font4">was obtained from each patient. Acute side effects on the skin, salivary glands, pharynx and esophagus, and larynx were measured using the </span><span class="font4" style="font-style:italic;">Radiation Therapy Oncology Group</span><span class="font4"> (RTOG) scoring system. The assessment includes grade 0 to grade 4, where grade 0 indicates no toxicity or no change , grade 1 indicates mild changes (dermatitis/mucositis/dysphagia), grade II indicates moderate and symptomatic (moist desquamation/patchy mucositis/sticky saliva and dysphagia ), grade III indicates severe changes (desquamation/confluent mucositis/dryness and dysphagia), grade IV indicates excruciating and debilitating changes (ulcer, bleeding, necrosis, complete obstruction or fistula). Quality of life was quantified with the Indonesian version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 ( EORTC QLQ-C30 ). The questionnaire is completed with patient self-assessment responses. The questionnaire consists of 30 items (physical, role, cognitive, emotional and social functioning), a Global Health Status ( GHS ), three symptom scales and six single item scales. All responses were converted to a 0–100 scale. Scores were calculated based on the EORTC QLQ-C30 scoring manual. Higher scores for the functional scale and for the global QOL scale indicate better QOL. For symptom-oriented scales and </span><a href="http://ojs.unud.ac.id/index.php/eum"><span class="font0">http://ojs.unud.ac.id/index.php/eum</span></a><span class="font0"> doi:10.24843.MU.2024.V13.i02.P14</span></p>
<p><span class="font4">items, higher scores correspond to higher levels of distressing symptoms.Acute adverse events were categorized by RTOG from 0 to 4. In the general health category and on the functional scale, “good” status was assigned an EORTC score of ≥ 50 points. In the symptom category, “good” status is given when an EORTC score is &lt;50 points. Chi Square tests were used to calculate mean scores and p values for the QOL scales. The significance of correlation between groups was determined based on a p value &lt;0.05 which was considered statistically significant.</span></p>
<h1><a name="bookmark2"></a><span class="font4" style="font-weight:bold;"><a name="bookmark3"></a>RESULTS</span></h1>
<p><span class="font4">The number of patients who met the inclusion and exclusion criteria was 52 people, consisting of 17 patients treated with the Cobalt-60 teletherapy device and 35 patients treated with the LINAC teletherapy device.The majority of patients treated with the LINAC teletherapy device were 35 people (63.7%), while the number of patients treated with the Cobalt-60 teletherapy device was 17 people (32.7%). The largest gender in this study was male, totaling 37 people (71.2%). The average age of patients in this study was 52.9 years. Patients in the 49-60 year age group were 26 people (50%) which was the largest. There were 14 (27%) patients aged 37-48 years, 10 (19.2%) patients aged 61-72 years, and 2 (3.8%) patients aged 24-36 years. The most common tumor location found in patients was the nasopharynx, namely 44 people (84.6%). Tumors in the pharynx were found in 3 people (5.8%). Other tumors were located in the oral cavity, sinonasal cavity, salivary glands, thyroid and neck (9.6%). The most prognostic stage diagnosis was stage 4A, namely 30 people (57.7%), followed by stage 4B with 8 people (15.4%), stage 4C with 7 people (13.5%), stage 4C with 6 people ( 11.5%). stage 3, and 1 person (1.9%) in stage 1.</span></p>
<p><span class="font4" style="font-weight:bold;">Table 1. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="font4">Patient Characteristics</span></p>
<table border="1">
<tr><td colspan="2" style="vertical-align:bottom;">
<p><span class="font4">Parameter</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Frequency</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Proportion</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">
<p><span class="font4">Cobalt-60</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">17</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">32.7</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font4">Teletherapy</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">LINAC</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">35</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">63.7</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">
<p><span class="font4">Man</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">37</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">71.2</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font4">Gender</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font4">^^^^^~</span></p></td><td style="vertical-align:top;">
<p><span class="font4">Woman</span></p></td><td style="vertical-align:top;">
<p><span class="font4">15</span></p></td><td style="vertical-align:top;">
<p><span class="font4">28.8</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">
<p><span class="font4">24–36</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">2</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">3.8</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font4">Age (Mean</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">37 –48</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">1 4</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">27, 0</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">± SD: 52.9 ±</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font4">Q 7λ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></p></td><td style="vertical-align:top;">
<p><span class="font4">49–60</span></p></td><td style="vertical-align:top;">
<p><span class="font4">26</span></p></td><td style="vertical-align:top;">
<p><span class="font4">50, 0</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font4">9.7)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">61–72</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">1 0</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">19, 2</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">
<p><span class="font4">Nasopharynx</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">44</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">84.6</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">
<p><span class="font4">Larynx _</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">3</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">5.8</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">
<p><span class="font4">Oral cavity</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">1</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">1.9</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font4">Tumor</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">Sinonasal cavity</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">1</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">1.9</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font4">Location</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font4">Gland saliva</span></p></td><td style="vertical-align:top;">
<p><span class="font4">1</span></p></td><td style="vertical-align:top;">
<p><span class="font4">1.9</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">
<p><span class="font4">Thyroid</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">1</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">1.9</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">
<p><span class="font4">Neck (DSFP)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">1</span></p></td><td style="vertical-align:bottom;">
<p><span class="font4">1.9</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:middle;">
<p><span class="font4">1</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">1</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">1.9</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font4">Prognosis</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">3</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">6</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">11.5</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font4">Stage</span></p></td><td style="vertical-align:top;">
<p><span class="font4">4A</span></p></td><td style="vertical-align:top;">
<p><span class="font4">30</span></p></td><td style="vertical-align:top;">
<p><span class="font4">57.7</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font4">(AJCC 8th)</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">4B</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">8</span></p></td><td style="vertical-align:middle;">
<p><span class="font4">15.4</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font4">4C</span></p></td><td style="vertical-align:top;">
<p><span class="font4">7</span></p></td><td style="vertical-align:top;">
<p><span class="font4">13.5</span></p></td></tr>
</table>
<p><span class="font4">In this study, the majority of patients experienced Grade 1 acute skin adverse events; Cobalt group 60 (88.2%), LINAC group (74.3%). In the salivary gland side effect parameters, it was found that the Cobalt 60 group experienced more severe side effects, Grade 2 (23.5%). In the Cobalt 60 group, a greater proportion of acute pharyngeal and esophageal adverse events were found in grade 1 (47%) and grade 2 (41.2%), similar results were observed in the LINAC group; most patients experienced grade 1 (57.1%) followed by grade 2 (34.3%). Two of the thirty-five patients in the LINAC group experienced grade 4 pharyngeal and esophageal side effects. Most patients in both groups experienced grade 1 laryngeal side effects. Based on statistical tests, there was no significant difference in acute side effects (p&lt;0.05) between patients using Cobalt-60 and LINAC teletherapy devices. However, it was found that all patients participating in the study had acute side effects on the skin, salivary glands, pharynx and esophagus, as well as the larynx.</span></p>
<p><span class="font4" style="font-weight:bold;">Table 2 . </span><span class="font4">Comparison effect side acute on both group</span></p>
<table border="1">
<tr><td rowspan="2" style="vertical-align:top;">
<p><span class="font2">Category</span></p></td><td colspan="5" style="vertical-align:bottom;">
<p><span class="font2">Cobalt-60 (Grade) </span><span class="font2" style="font-style:italic;">n</span><span class="font2"> =17</span></p></td><td colspan="5" style="vertical-align:bottom;">
<p><span class="font2">LINAC (Grades) </span><span class="font2" style="font-style:italic;">n</span><span class="font2"> =35</span></p></td><td style="vertical-align:top;">
<p><span class="font2">p value</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font2">0</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">1</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">2</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">3</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">4</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">0</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">1</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">2</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">3</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">4</span></p></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">Skin [ </span><span class="font2" style="font-style:italic;">n</span><span class="font2"> ] (%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">0</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">15 (88. 2%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">2 (11. 8%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">0</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">0</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">1 (2.9 %)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">26 (74. 3%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">8 (22. 8%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">0</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">0</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.472</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font2">Gland Saliva [ </span><span class="font2" style="font-style:italic;">n</span><span class="font2"> ] (%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">0</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">13 (76. 5%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">4 (23. 5%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">0</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">0</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">0</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">29 (82. 9%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">6 (17. 1%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">0</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">0</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.584</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font2">Pharynx and Esophagus [ </span><span class="font2" style="font-style:italic;">n</span><span class="font2"> ] (%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">0</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">8 (47. 0%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">7 (41. 2%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">2 (11. 8%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">0</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">1 (2.9 %)</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">20 (57. 1%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">12 (34. 3%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">0</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">2 (5.7 %)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.204</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">Larynx [ </span><span class="font2" style="font-style:italic;">n</span><span class="font2"> ] (%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">2 (11. 8%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">11 (64. 6%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">2 (11. 8%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">2 (11. 8%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">0</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">8 (22. 9%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">11 (31. 4%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">6 (17. 1%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">8 (22. 9%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">2 (5.7 %)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.227</span></p></td></tr>
</table>
<p><span class="font4">Note: Assessment of acute side effects according to the Radiation Therapy Oncology Group (RTOG) criteria, morbidity levels (e.g. Grade 0 –no change, grade IV – excruciating changes) is described in the 'Materials and methods' section. This data is objective – with clinical judgment.</span></p>
<p><span class="font4">Most of the patients' global health status was generally in &quot;good&quot; condition. In the functional scale category, the physical, emotional and emotional function variables are mostly in &quot;good&quot; condition. However, for role function, almost half of the patients treated with LINAC teletherapy devices were in “poor” condition. The role function has the highest number of patients in “bad” condition. Cognitive and emotional functions in both groups were all in &quot;good&quot; condition.</span></p>
<p><span class="font4">In the symptom scale category, fatigue was the symptom most frequently experienced by patients in both groups. Complaints of shortness of breath and diarrhea were not found in patients treated with Cobalt-60. Financial difficulties were not found in either group. Based on statistical tests, there was no significant difference in quality of life (p&gt;0.05) between patients who used Cobalt-60 and LINAC teletherapy.</span></p>
<p><span class="font4" style="font-weight:bold;">Table 3 . &nbsp;&nbsp;&nbsp;</span><span class="font4">Comparison quality live on both group</span></p>
<table border="1">
<tr><td rowspan="2" style="vertical-align:middle;">
<p><span class="font2">Parameter</span></p></td><td rowspan="2" style="vertical-align:bottom;">
<p><span class="font2">EORTC QLQ C30 Mean Score ±</span></p>
<p><span class="font2">SD</span></p></td><td colspan="2" style="vertical-align:bottom;">
<p><span class="font2">Cobalt-60 </span><span class="font2" style="font-style:italic;">n</span><span class="font2"> =17</span></p></td><td colspan="2" style="vertical-align:bottom;">
<p><span class="font2">LINAC </span><span class="font2" style="font-style:italic;">n</span><span class="font2"> =35</span></p></td><td rowspan="2" style="vertical-align:middle;">
<p><span class="font2">p value</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font2">Good</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">Bad</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">Good</span></p></td><td style="vertical-align:middle;">
<p><span class="font2">Bad</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">Global Health Status [ </span><span class="font1" style="font-style:italic;">n</span><span class="font1"> ](%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">65.5 ±</span></p>
<p><span class="font1">18.1</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">13 (76.5%)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">4 (23.5%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">33 (94.3%)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">2 (5.7%)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">0.06</span></p></td></tr>
<tr><td colspan="7" style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Functional Scale</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">Physical function [ </span><span class="font1" style="font-style:italic;">n</span><span class="font1"> ](</span></p>
<p><span class="font1">%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">71.9 ±</span></p>
<p><span class="font1">25.1</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">13 (76.5%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">4 (23.5%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">30 (85.7%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">5 (14.3%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">0.40</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">Role Function [ </span><span class="font1" style="font-style:italic;">n</span><span class="font1"> ]( %)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">51.9 ±</span></p>
<p><span class="font1">31.8</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">10 (58.8%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">7 (41.2%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">18 (51.4%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">17 (48.6%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">0.61</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">Emotional Function [ </span><span class="font1" style="font-style:italic;">n</span><span class="font1"> ]( %)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">81.9 ±</span></p>
<p><span class="font1">20.1</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">16 (94.1%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">1 (5.9%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">33 (94.3%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">2 (5.7%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">0.98</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">Cognitive function [ </span><span class="font1" style="font-style:italic;">n</span><span class="font1"> ](</span></p>
<p><span class="font1">%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">89.1 ±</span></p>
<p><span class="font1">15.8</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">17 (100%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">0 (0%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">35 (100%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">0 (0%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">-</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">Social function [ </span><span class="font1" style="font-style:italic;">n</span><span class="font1"> ]( %)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">85.9 ±</span></p>
<p><span class="font1">16.6</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">17 (100%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">0 (0%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">35 (100%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">0 (0%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">-</span></p></td></tr>
<tr><td colspan="7" style="vertical-align:bottom;">
<p><span class="font1" style="font-weight:bold;">Symptoms Scale</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">Fatigue [ </span><span class="font1" style="font-style:italic;">n</span><span class="font1"> ]( %)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">50.0 ±</span></p>
<p><span class="font1">31.2</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">4 (23.5%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">13 (76.5%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">4 (11.4%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">31 (88.6%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">0.26</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">Nauseous or</span></p>
<p><span class="font1">Vomiting [ </span><span class="font1" style="font-style:italic;">n</span><span class="font1"> ]( %)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">20.8 ±</span></p>
<p><span class="font1">30.4</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">14 (82.4%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">3 (17.6%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">29 (82.9%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">6 (17.1)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">0.96</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">Pain [ </span><span class="font1" style="font-style:italic;">n</span><span class="font1"> ]( %)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">36.2 ±</span></p>
<p><span class="font1">24.2</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">14 (82.4%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">3 (17.6%))</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">29 (82.9%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">6 (17.1%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">0.96</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">Dyspnea [ </span><span class="font1" style="font-style:italic;">n</span><span class="font1"> ]( %)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">8.3 ± 19.7</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">17 (100%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">0 (0%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">33 (94.3%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">2 (5.7%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">0.32</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">Insomnia [ </span><span class="font1" style="font-style:italic;">n </span><span class="font1">](%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">23.7 ±</span></p>
<p><span class="font1">30.5</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">14 (82.4%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">3 (17.6%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">28 (80.0%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">7 (20.0%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">0.84</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">Lost Appetite [ </span><span class="font1" style="font-style:italic;">n</span><span class="font1"> ]( %)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">24.4 ±</span></p>
<p><span class="font1">35.0</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">15 (88.2%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">2 (11.8%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">26 (74.3%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">9 (25.7%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">0.25</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">Constipation [ </span><span class="font1" style="font-style:italic;">n</span><span class="font1"> ]( %)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">26.3 ±</span></p>
<p><span class="font1">30.5</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">13 (76.5%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">4 (23.5%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">26 (74.3%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">9 (25.7%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">0.86</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">Diarrhea [ </span><span class="font1" style="font-style:italic;">n </span><span class="font1">](%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">4.5±13.2</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">17 (100%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">0 (0%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">34 (97.1%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">1 (2.9%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">0.48</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">Difficulty</span></p>
<p><span class="font1">Finance [ </span><span class="font1" style="font-style:italic;">n</span><span class="font1"> ](</span></p>
<p><span class="font1">%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">0.0±0.0</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">17 (100%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">0(0%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">35 (100%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">0 (0%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">-</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">Fatigue [ </span><span class="font1" style="font-style:italic;">n</span><span class="font1"> ]( %)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">50.0 ±</span></p>
<p><span class="font1">31.2</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">4 (23.5%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">13 (76.5%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">4 (11.4%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">31 (88.6%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">0.26</span></p></td></tr>
</table>
<p><span class="font4">Note: Assessment of quality of life according to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 as described in the 'Materials and methods' section. This data is subjective – reported by the patient.</span></p>
<h1><a name="bookmark4"></a><span class="font4" style="font-weight:bold;"><a name="bookmark5"></a>DISCUSSION</span></h1>
<p><span class="font4">In this study, the majority of participants were men (71.2%) with an average age of 52.9 ± 9.7 years. The primary location of the tumor was found in the nasopharynx (84.6%) and the prognostic stage at diagnosis according to the American Joint Committee on Cancer (AJCC) 8th edition was advanced stage 4A (57.7%), 4B (15.4%) and 4C (13.5%). This finding is in accordance with the theory that men are a population that has a greater risk factor for developing head and neck cancer, where the supporting factors for this cancer are the consumption of cigarettes and alcoholic drinks. The trigger factors for oronasopharyngeal cancer are HPV and EBV infections, the tendency of which continues to increase, causing the prevalence of oronasopharyngeal cancer to exceed the incidence of laryngeal and hypopharyngeal cancer.<sup>11</sup> Regarding the findings of many patients diagnosed with advanced stages in</span></p>
<p><span class="font4">this study, pathologically, the symptoms of nasopharyngeal cancer tend to be ignored by patients because the main tumor grows in the physiological cavity of the body. Therefore, when symptoms appear, it is known that the tumor has grown quite large or metastasized. <sup>12</sup></span></p>
<p><span class="font4">Radiation to the head and neck causes acute side effects affecting the skin, oral mucosa, salivary glands, esophagus, etc., which can hamper therapy and reduce the patient's quality of life. Acute side effects after radiotherapy in this study were measured objectively by RTOG assessment. In this study, we did not find a relationship between the type of teletherapy device used and acute side effects on the skin (p=0.472), salivary glands (p=0.584), pharynx and esophagus (p=0.204), or larynx (p=0.227 ).</span></p>
<p><span class="font4">Skin erythema (RTOG grade 1) was experienced by the majority of patients after radiotherapy in this study with Cobalt 60 (88.2%) and LINAC (74.3%). These findings are similar to a study conducted by Chugh et al, where the majority of participants undergoing radiotherapy with LINAC experienced grade 1-2 skin side effects. <sup>13</sup> However, this contradicts the findings of Allal et al, who found that most participants experienced more severe skin side effects (grade 3-4). <sup>14</sup></span></p>
<p><span class="font4">Most patients in the Cobalt and LINAC groups had grade 1 salivary gland side effects (76.5% and 82.9%, respectively), in which the oral cavity was slightly drier, and saliva was slightly thicker than normal. Dry mouth (xerostomia) is the most common side effect that occurs after radiation for head and neck cancer. <sup>15</sup> RTOG xerostomia grades 3-4 were statistically directly associated with decreased emotional and social functioning as well as increased fatigue and difficulty sleeping. <sup>16</sup> In this study, no patient had normal saliva production after completing one dose of head and neck radiotherapy. Symptoms of xerostomia can persist for up to 5 years after radiotherapy. <sup>17</sup></span></p>
<p><span class="font4">Almost all post-radiotherapy patients complained of pharyngeal and esophageal side effects (100% in the Cobalt group and 97.1% in the (LINAC) group). Swallowing function may be impaired due to several abnormal tissue changes including edema, neuropathy, and fibrosis. We found a low proportion of RTOG grade 3–4 acute adverse events in the pharynx and esophagus (11.8% in the Cobalt group and 5.7% in the LINAC group). A similar study by Van der Laan, suggested an increase in the proportion of swallowing difficulties (dysphagia) over time; in grades 3-4, it increased 6% at week 3 and 26% at week 6 postradiotherapy. <sup>18</sup> There was a significant relationship between severe xerostomia (grade 3-4) and severe acute and chronic dysphagia (grade 3-4), p=&lt;0.0001. <sup>19</sup></span></p>
<p><span class="font4">Progressive laryngeal edema and laryngeal fibrosis can cause voice and swallowing disorders. Voice changes are related to radiation dose to the larynx, pharynx, and oral cavity. More specifically, adverse effects on the larynx (grade ≥ 2) occurred after exposure to 66 Gy to this anatomical structure. <sup>20</sup> In this study, the proportion of patients who received a total radiation dose of 63-70 Gy</span></p>
<p><span class="font4">experienced laryngeal side effects varying from grade 0-3 in the Cobalt 60 group (11.8%, 64.6%, 11.8%, 11.8%), and grades 0-4 in the LINAC group (22.9%, 31.4%, 17.1%, 22.9%, 5.7%).</span></p>
<p><span class="font4">This study shows that there is no significant relationship between the type of teletherapy device used and the quality of life of head and neck cancer patients after radiotherapy. Although not significant, we found some differences between the two groups of participants. The group that received irradiation with the LINAC device had a “good” general health condition (EORTC score≥50 points) with a higher percentage (94.3%) compared to the Cobalt 60 group (76.5%). The average general health status score for all participants in this study (65.5 ± 18.1) was lower than in previous similar studies. Kao got 67.9 ± 14.8, Hammerlid 73.2 ± 21.3 and Liao 70.9 ± 22.1. <sup>21-23</sup></span></p>
<p><span class="font4">Among the five functional aspects, the aspect that is most affected is role function. Role function is the patient's ability to carry out daily activities, hobby activities, and work or profession. <sup>24</sup> In this study, we found that the lowest average EORTC QLQ C30 score was in the patient role function category, namely 51.9 ± 31.8 and there was only a slight difference in the proportion of &quot;good&quot; and &quot;bad&quot; between the two groups. The results of previous research also show that the role function category is the lowest of all functions. <sup>24,25</sup> On the other hand, all participants in this study had “good” functioning in the cognitive (mean 89.1 ± 15.8) and social (mean 85.9 ± 16.6) categories. This stance is contrary to the study conducted by Leung et al. where the role function score is the highest among other functions. <sup>26 </sup>However, role function is the first gateway to improve quality of life, as it will improve the other counterparts.<sup>27 </sup>The differences of function recovery among different cultural backgrounds are strongly encouraged for further research.</span></p>
<p><span class="font4">The quality of life of cancer sufferers will decrease after cancer therapy. The factors causing the decline in quality of life are still being debated, one of which is socioeconomic factors. The study by Kao et al. did not find a significant association, but a study by Liao et al. found that patients with high socioeconomic status had better functioning effects. <sup>21,22</sup> Janda M et al. observed that high levels of education and marital status were associated with better functioning and quality of life. <sup>28</sup></span></p>
<p><span class="font4">The EORTC QLQ C30 symptom scale in this study showed an average score of ≤50. This symptom scale has the lowest score compared to the other two scales. The symptom experienced by the majority of patients was fatigue (mean 50.0 ± 31.2) where the percentage in the &quot;bad&quot; category was lower in the Cobalt 60 group (76.5%) and higher in the LINAC group (77.6 %). Several other studies also found that of all the symptoms listed on the scale, fatigue was the most frequently experienced by patients. <sup>22,28,29</sup></span></p>
<h1><a name="bookmark6"></a><span class="font4" style="font-weight:bold;"><a name="bookmark7"></a>CONCLUSIONS AND SUGGESTIONS</span></h1>
<p><span class="font4">Despite the development of the LINAC and its ability to replace the Cobalt 60 machine, it remains unproven whether one is significantly more useful than the other. However, it is worth mentioning that patients who received radiotherapy with the LINAC device had a higher proportion of “good” general health conditions, compared with the Cobalt 60 group.</span></p>
<p><span class="font4">Follow-up studies comparing the patient's condition before, after radiotherapy, and follow-up at 1 year can be carried out to determine the evolution of quality of life and side effects. In addition, further studies to find the relationship between demographic data and radiation dose with quality of life and acute side effects should be carried out to determine factors that can worsen and alleviate the patient's condition.</span></p>
<h1><a name="bookmark8"></a><span class="font4" style="font-weight:bold;"><a name="bookmark9"></a>THANK-YOU NOTE</span></h1>
<p><span class="font4">We would like to express our deepest gratitude to all parties who have played a role in completing this research and publishing this article. We are grateful for the generous participation of the study participants, whose time and cooperation were indispensable in collecting the necessary data. We extend our thanks to the healthcare professionals, nurses, and technicians who provided support in data collection, sample analysis, and patient care. In addition, we thank Prof. Hospital. Dr. IGNG Ngoerah has financially supported this research, enabling scientific investigation and health advancement.</span></p>
<h1><a name="bookmark10"></a><span class="font4" style="font-weight:bold;"><a name="bookmark11"></a>REFERENCES</span></h1>
<ul style="list-style:none;"><li>
<p><span class="font4">1. &nbsp;&nbsp;&nbsp;Global Cancer Observatory. </span><span class="font4" style="font-style:italic;">International Agency for Research on Cancer</span><span class="font4"> .; 2018. Accessed April 18, 2020. </span><a href="https://gco.iarc.fr/today/data/factsheets/populations/360"><span class="font4">https://gco.iarc.fr/today/data/factsheets/populations/360</span></a><span class="font4"> -indonesia-fact-sheets.pdf</span></p></li>
<li>
<p><span class="font4">2. &nbsp;&nbsp;&nbsp;Joshi P, Dutta S, Chaturvedi P, Nair S. Head and Neck Cancers in Developing Countries. </span><span class="font4" style="font-style:italic;">Rambam Maimonides &nbsp;&nbsp;&nbsp;&nbsp;Med</span><span class="font4"> &nbsp;&nbsp;&nbsp;&nbsp;J. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014;5(2):e0009.</span></p></li></ul>
<p><span class="font4">doi:10.5041/RMMJ.10143</span></p>
<ul style="list-style:none;"><li>
<p><span class="font4">3. &nbsp;&nbsp;&nbsp;National Cancer Institute. Radiation Therapy and You: Support for People with Cancer. </span><a href="http://www.cancer.gov"><span class="font4">www.cancer.gov</span></a></p></li>
<li>
<p><span class="font4">4. &nbsp;&nbsp;&nbsp;Celebrating the 60th anniversary of the world's first cancer treatment with cobalt-60 radiation. </span><span class="font4" style="font-style:italic;">London Health Sciences Centre</span><span class="font4"> . Published online 2011. Accessed April 18, 2020. </span><a href="https://www.lhsc.on.ca/about-lhsc/celebrating-the-60th-anniversary-of-the-worlds-first-cancer-treatment-with-cobalt-"><span class="font4">https://www.lhsc.on.ca/about-lhsc/celebrating-the-60th-anniversary-of-the-worlds-first-cancer-treatment-with-cobalt-</span></a><span class="font4"> 60</span></p></li>
<li>
<p><span class="font4">5. &nbsp;&nbsp;&nbsp;Wiedemann H. </span><span class="font4" style="font-style:italic;">Particle Accelerator Physics</span><span class="font4"> . Springer International Publishing; 2015. doi:10.1007/978-3-319-18317-6</span></p></li>
<li>
<p><span class="font4">6. &nbsp;&nbsp;&nbsp;Reddy K.S. 50 Years of Cancer Control in India. Choice of Teletherapy Unit: Cobalt 60 Unit vs Linear Accelerator. 2019. Pp.79-87.</span></p></li>
<li>
<p><span class="font4">7. &nbsp;&nbsp;&nbsp;Kim JH, Jenrow KA, Brown SL. Mechanisms of radiation-induced normal tissue toxicity and implications for future clinical trials. </span><span class="font4" style="font-style:italic;">Radiat Oncol J</span><span class="font4"> . 2014;32(3):103-115. doi:10.3857/roj.2014.32.3.103</span></p></li>
<li>
<p><span class="font4">8. &nbsp;&nbsp;&nbsp;Cox JD, Stetz J, Tax TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC). </span><span class="font4" style="font-style:italic;">International Journal of Radiation Oncology*Biology*Physics</span><span class="font4"> . &nbsp;1995;31(5):1341-1346.</span></p></li></ul>
<p><span class="font4">doi:10.1016/0360-3016(95)00060-C</span></p>
<ul style="list-style:none;"><li>
<p><span class="font4">9. &nbsp;&nbsp;&nbsp;Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995 Mar &nbsp;&nbsp;&nbsp;&nbsp;30;31(5):1341-6. &nbsp;&nbsp;&nbsp;&nbsp;doi: &nbsp;&nbsp;&nbsp;&nbsp;10.1016/0360-</span></p></li></ul>
<p><span class="font4">3016(95)00060-C. PMID: 7713792</span></p>
<ul style="list-style:none;"><li>
<p><span class="font4">10. &nbsp;&nbsp;&nbsp;Brook I. Late side effects of radiation treatment for head and neck cancer. Radiat Oncol J. 2020;38(2):84-92. doi:10.3857/roj.2020.00213</span></p></li>
<li>
<p><span class="font4">11. &nbsp;&nbsp;&nbsp;Rettig EM, D'Souza G. Epidemiology of Head and Neck Cancer. </span><span class="font4" style="font-style:italic;">Surg Oncol Clin N Am</span><span class="font4"> . 2015;24(3):379-396. doi:10.1016/j.soc.2015.03.001</span></p></li>
<li>
<p><span class="font4">12. &nbsp;&nbsp;&nbsp;Georgopoulos R, Liu JC. Examination of the Patient with Head and Neck Cancer. </span><span class="font4" style="font-style:italic;">Surg Oncol Clin N Am</span><span class="font4"> . 2015;24(3):409-421. doi:10.1016/j.soc.2015.03.003</span></p></li>
<li>
<p><span class="font4">13. &nbsp;&nbsp;&nbsp;Chugh R, Bisht Y s, Nautiyal V, Jindal R. Factors Influencing the Severity of Acute Radiation-Induced Skin and Mucosal Toxicity in Head and Neck Cancer. </span><span class="font4" style="font-style:italic;">Cureus</span><span class="font4"> . 2021;13(9). doi:10.7759/cureus.18147</span></p></li>
<li>
<p><span class="font4">14. &nbsp;&nbsp;&nbsp;Allal AS, Maire D, Becker M, Dulguerov P. Feasibility and early results of accelerated radiotherapy for head and neck carcinoma in the elderly. </span><span class="font4" style="font-style:italic;">Cancer</span><span class="font4"> . 2000;88(3):648-652.</span></p></li>
<li>
<p><span class="font4">15. &nbsp;&nbsp;&nbsp;Bansal M, Mohanti BK, Shah N, Chaudhry R, Bahadur S, Shukla NK. Radiation related morbidities and their impact on quality of life in head and neck cancer patients receiving radical radiotherapy. </span><span class="font4" style="font-style:italic;">Quality of Life Research</span><span class="font4"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2004;13(2):481-488.</span></p></li></ul>
<p><span class="font4">doi:10.1023/B:QURE.0000018491.80646.bc</span></p>
<ul style="list-style:none;"><li>
<p><span class="font4">16. &nbsp;&nbsp;&nbsp;Strojan P, Hutcheson KA, Eisbruch A, et al. Treatment of late sequelae after radiotherapy for head and neck cancer. </span><span class="font4" style="font-style:italic;">Cancer Treat</span><span class="font4"> Rev. 2017;59:79-92. doi:10.1016/j.ctrv.2017.07.003</span></p></li>
<li>
<p><span class="font4">17. &nbsp;&nbsp;&nbsp;Meßmer MB, Thomsen A, Kirste S, Becker G, Momm F. Xerostomia after radiotherapy in the head&amp;amp;neck area: &nbsp;Long-term observations. </span><span class="font4" style="font-style:italic;">Radiotherapy and</span></p></li></ul>
<p><span class="font4" style="font-style:italic;">Oncology</span><span class="font4"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2011;98(1):48-50.</span></p>
<p><span class="font4">doi:10.1016/j.radonc.2010.10.013</span></p>
<ul style="list-style:none;"><li>
<p><span class="font4">18. &nbsp;&nbsp;&nbsp;van der Laan HP, Bijl HP, Steenbakkers RJHM, et al. Acute symptoms during the course of head and neck radiotherapy or chemoradiation are strong predictors of late dysphagia. </span><span class="font4" style="font-style:italic;">Radiotherapy and Oncology</span><span class="font4"> . 2015;115(1):56-62. doi:10.1016/j.radonc.2015.01.019</span></p></li>
<li>
<p><span class="font4">19. &nbsp;&nbsp;&nbsp;Mortensen HR, Overgaard J, Jensen K, et al. Factors associated with acute and late dysphagia in the DAHANCA 6 &amp;amp; 7 randomized trials with accelerated radiotherapy for head and neck cancer. </span><span class="font4" style="font-style:italic;">Acta Oncol &nbsp;&nbsp;&nbsp;&nbsp;(Madr)</span><span class="font4"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;2013;52(7):1535-1542.</span></p></li></ul>
<p><span class="font4">doi:10.3109/0284186X.2013.824609</span></p>
<ul style="list-style:none;"><li>
<p><span class="font4">20. &nbsp;&nbsp;&nbsp;Rancati T, Schwarz M, Allen AM, et al. Radiation Dose–Volume Effects in the Larynx and Pharynx. </span><span class="font4" style="font-style:italic;">International &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Journal &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Radiation</span></p></li></ul>
<p><span class="font4" style="font-style:italic;">Oncology*Biology*Physics</span><span class="font4"> . &nbsp;&nbsp;2010;76(3):S64-S69.</span></p>
<p><span class="font4">doi:10.1016/j.ijrobp.2009.03.079</span></p>
<ul style="list-style:none;"><li>
<p><span class="font4">21. &nbsp;&nbsp;&nbsp;Kao NH, Iyer NG, Chua A, Nagadia RH. Early quality of life outcomes after surgery in head and neck cancer survivors with EORTC QLQ-C30 and EORTC QLQ-HN35 in an Asian tertiary center . </span><span class="font4" style="font-style:italic;">Supportive Care in Cancer</span><span class="font4"> . 2022;30(5):4537-4546. doi:10.1007/s00520-022-06871-4</span></p></li>
<li>
<p><span class="font4">22. &nbsp;&nbsp;&nbsp;Hammerlid E, Adnan A, Silander E. Population-based reference values for the European Organization for Research and Treatment of Cancer Head and Neck module. </span><span class="font4" style="font-style:italic;">Head Neck</span><span class="font4"> . &nbsp;2017;39(10):2036-2047.</span></p></li></ul>
<p><span class="font4">doi:10.1002/hed.24870</span></p>
<ul style="list-style:none;"><li>
<p><span class="font4">23. &nbsp;&nbsp;&nbsp;Liao LJ, Hsu WL, Lo WC, Cheng PW, Shueng PW, Hsieh CH. Health-related quality of life and utility in head and neck cancer survivors. </span><span class="font4" style="font-style:italic;">BMC Cancer</span><span class="font4"> . 2019;19(1):425. doi:10.1186/s12885-019-5614-4</span></p></li>
<li>
<p><span class="font4">24. &nbsp;&nbsp;&nbsp;Meier A, Yopp A, Mok H, Kandunoori P, Tiro J, Singal AG. Role functioning is associated with survival in patients with hepatocellular carcinoma. </span><span class="font4" style="font-style:italic;">Quality of Life Research</span><span class="font4"> . 2015;24(7):1669-1675. doi:10.1007/s11136-014-0895-1</span></p></li>
<li>
<p><span class="font4">25. &nbsp;&nbsp;&nbsp;Sherman AC, Simonton S, Adams DC, Vural E, Owens B, Hanna E. Assessing Quality of Life in Patients With Head and Neck Cancer. </span><span class="font4" style="font-style:italic;">Arch Otolaryngol Head Neck Surg</span><span class="font4"> . 2000;126(4):459. doi:10.1001/archotol.126.4.459</span></p></li>
<li>
<p><span class="font4">26. &nbsp;&nbsp;&nbsp;Wan Leung S, Lee TF, Chien CY, Chao PJ, Tsai WL, Fang FM. Health-related Quality of life in 640 head and neck cancer survivors after radiotherapy using EORTC QLQ-C30 and QLQ-H&amp;amp;N35 questionnaires. </span><span class="font4" style="font-style:italic;">BMC Cancer</span><span class="font4"> . 2011;11(1):128. doi:10.1186/1471-2407-11-128</span></p></li>
<li>
<p><span class="font4">27. &nbsp;&nbsp;&nbsp;Su T.T., Azzani M., Tan F.L., Loh S.Y. Breast cancer survivors: Return to work and wage loss in selected hospitals in Malaysia. Support. Care Cancer. 2018;26:1617–1624. doi: 10.1007/s00520-017-3987-y.</span></p></li>
<li>
<p><span class="font4">28. &nbsp;&nbsp;&nbsp;Beck AJCC, Kieffer JM, Retèl VP, et al. Mapping the EORTC QLQ-C30 and QLQ-H&amp;amp;N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained? </span><span class="font4" style="font-style:italic;">PLoS One</span><span class="font4"> . &nbsp;2019;14(12).</span></p></li></ul>
<p><span class="font4">doi:10.1371/journal.pone.0226077</span></p>
<ul style="list-style:none;"><li>
<p><span class="font4">29. &nbsp;&nbsp;&nbsp;Iravani K, Jafari P, Akhlaghi A, Khademi B. Assessing whether EORTC QLQ-30 and FACT-G measure the same constructs of quality of life in patients with total laryngectomy. </span><span class="font4" style="font-style:italic;">Health Qual Life Outcomes</span><span class="font4"> . 2018;16(1):183. doi:10.1186/s12955-018-1012-x</span></p>
<div><img src="https://jurnal.harianregional.com/media/105396-4.jpg" alt="" style="width:66pt;height:24pt;">
</div><br clear="all"></li></ul>
<p><a href="http://ojs.unud.ac.id/index.php/eum"><span class="font0">http://ojs.unud.ac.id/index.php/eum</span></a></p>
<p><span class="font0">doi:10.24843.MU.2024.V13.i02.P14</span></p>
<p><span class="font0">P a g e </span><span class="font0" style="font-weight:bold;">79</span></p>